ResearcherLund UniversityNo recent work listed
Carlos Urey
Matched on ORCID iD 0000-0001-7743-4630; OpenAlex author ID A5060781715. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers
Papers 4
- Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. Co-author DOI 10.1080/00365521.2017.1290134↗
- Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.12050↗
- Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression. First author PMID 25275019↗
- Comparison of MUC4 expression in primary pancreatic cancer and paired lymph node metastases. First author DOI 10.3109/00365521.2013.832368↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Roland E. Andersson · 4 shared papers, 2013–2017 · strength 0.26
- Paper Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ducta… DOI 10.21873/anticanres.12050↗
- Paper Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvan… DOI 10.1080/00365521.2017.1290134↗
- Paper Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression. PMID 25275019↗
- Daniel Ansari · 4 shared papers, 2013–2017 · strength 0.26
- Paper Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ducta… DOI 10.21873/anticanres.12050↗
- Paper Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvan… DOI 10.1080/00365521.2017.1290134↗
- Paper Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression. PMID 25275019↗
- Bodil Andersson · 2 shared papers, 2017 · strength 0.17
- Paper Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ducta… DOI 10.21873/anticanres.12050↗
- Paper Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvan… DOI 10.1080/00365521.2017.1290134↗
- Monika Posaric Bauden · 2 shared papers, 2013–2014 · strength 0.09
- Chinmay Gundewar · 1 shared paper, 2013 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.